Cancer Registry Software Market Size, Share, and Trends 2024 to 2034

Cancer Registry Software Market (By Software: Cross disciplinary, Specific; By Deployment Model: On-premise, Cloud-based; By Component: Commercial, Public; By End Use: Government and third party, Private payers, Hospital and medical practice, Pharma biotech and medical device companies, Research institutes; By Functionality) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024 – 2033

  • Last Updated : June 2024
  • Report Code : 1625
  • Category : Healthcare

Cancer Registry Software Market Size and Growth 2024 to 2033

The global cancer registry software market size was valued at USD 59.02 million in 2023 and is expected to surpass around USD 143.62 million by 2033, growing at a CAGR of 9.3% from 2024 to 2033. 

Cancer Registry Software Market Size 2024 to 2033

Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare

Cancer Registry Software Market Key Takeaways

  • North America led the global market with the highest market share of 33.64% in 2023.
  • By software, the standalone segment has held the largest market share in 2023.
  • By deployment model, the on-premise segment captured the biggest revenue share in 2023.
  • By component, the commercial segment registered the maximum market share in 2023.

U.S. Cancer Registry Software Market Size and Growth 2024 to 2033

The U.S. cancer registry software market size was estimated at USD 13.92 million in 2023 and is predicted to be worth around USD 35.94 million by 2033, at a CAGR of 9.9% from 2024 to 2033.

U.S. Cancer Registry Software Market Size 2024 to 2033

North America dominated the cancer registry software market in 2023. The U.S. dominated the cancer registry software market in North America region. The North America region has presence of major market players operating in the cancer registry software market. The cancer registry software market in this region is growing due to the rising prevalence of cancer. In addition, due to high investments in the technology, the demand for cancer registry software is rising on a large scale in North America.

Cancer Registry Software Market Share, By Region, 2023 (%)

Asia-Pacific, on the other hand, is expected to develop at the fastest rate during the forecast period. The government of emerging nations such as Japan and China are taking constant efforts for the development of the cancer registry software market. Moreover, the key market players are collaborating with the government agencies for the expansion of the healthcare sector. This factor is driving the growth of the cancer registry software market in Asia-Pacific region.

Europe Cancer Registry Software Market Size and Growth 2024 to 2033

The Europe cancer registry software market size was calculated at USD 16.00 million in 2023 and is projected to expand around USD 41.08 million by 2033, poised to grow at a CAGR of 9.9% from 2024 to 2033.

Year Market Size (USD Million)
2023 16.00
2024 17.58
2025 19.33
2026 21.24
2027 23.34
2028 25.65
2029 28.18
2030 30.97
2031 34.02
2032 37.38
2033 41.08

 

Cancer Registry Software Market Growth Factors

The cancer registry software is database or an information system which helps to collect the information regarding cancer patients. One of the key factors driving the growth of the global cancer registry software market is growing incidence of cancer globally. The cancer registry software helps to track and monitor the health of patients who are suffering from cancer. The data collected with the help of cancer registry software helps researchers and healthcare practitioners to develop therapeutics for the treatment of cancer. Thus, the global cancer registry software market is expected to grow in the coming years.

In addition, the growing geriatric population is also driving the growth of the cancer registry software market over the forecast period. The data collected from the cancer registry software helps to control the cancer from spreading all around the world. This software also helps government to track the patients in a particular location and region. As a result, this factor is supporting the growth of the global cancer registry software market.

Another factor boosting the growth of the global cancer registry software market is adoption of advanced technology. The electronic health records are also utilized tremendously for keeping track of the data. Thus, the cancer registry software is being adopted on a large scale across all research centers and healthcare centers. Furthermore, the government of developed and developing countries is taking constant efforts for the growth of the global cancer registry software market during the forecast period.

On the other hand, the data privacy and security are one of the biggest challenges for the growth of the global cancer registry software market. The data and information collected with the help of cancer registry software can be easily hacked and this data can be misused by hackers. Thus, this factor is hindering the cancer registry software market.

Cancer Registry Software Market Scope

Report Coverage Details
Cancer Registry Software Market Size in 2023 USD 59.02 Million
Cancer Registry Software Market Size by 2033 USD 143.62 Million
Growth Rate from 2024 to 2033 CAGR of 9.3%
Largest Market North America
Fastest Growing Region Asia Pacific
Base Year 2023
Forecast Period 2024 to 2033
Segments Covered By Software, By Deployment Model, By Component, By End User, and By Functionality
Regions Covered North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

 

Software Insights

The standalone segment dominated the cancer registry software market in 2023. The standalone cancer registry software is integrated with latest and advanced features. It is also easy to use and operate. The standalone cancer registry software also helps in the reduction of overhead costs. Thus, all of these factors are propelling the growth of the segment.

The integrated segment is expected to witness strong growth during the forecast period. The integrated cancer registry software helps to collaborate with the hospitals’ software. This software helps to locate patients in any location. The integrated cancer registry software also assists to track and monitor the health of patients.

Deployment Model Insights

The on-premise segment dominated the cancer registry software market in 2023. The on-premise cancer registry software is mostly adopted by research institutes who are doing research on cancer. The on-premise cancer registry software is embedded with advanced features which help to store data easily. The on-premise cancer registry software is less risky as compared to other types of models. Thus, the on-premise cancer registry software is widely used in hospitals and research centers.

The cloud-based segment is fastest growing segment of the cancer registry software market in 2023. The cloud-based cancer registry software can be integrated with the real time data and standard guidelines. This software helps in the reduction of information technology overhead costs. In addition, the cloud-based cancer registry software is efficient in nature, which is driving the growth of the segment.

Component Insights

The commercial segment dominated the cancer registry software market in 2023. The data stored in the commercial database is quite safe as compared to public database. The data stored in the commercial database can be easily tracked. The commercial database can be used across research centers and government agencies. Thus, the commercial segment is rising at a rapid pace.

The public segment is fastest growing segment of the cancer registry software market in 2023. The public database is used for the various cancer research programs. The utilization of public database is growing due to the growing number of research centers all over the globe. The public database can help to track patient data from any corner of the world.

End Use Insights

The government and third-party segment dominated the cancer registry software market in 2023. The government of established and emerging nations is adopting cancer registry software on the large scale. This software helps to track and monitor cancer patients in their respective region. In addition, the investments made by government for the implementation of cancer registry software in hospitals. This factor is boosting the growth of the global cancer registry software market over the forecast period. 

The research institutes segment is fastest growing segment of the cancer registry software market in 2023. The cancer registry software is widely used in research institutes due to growing prevalence of cancer. The growing research and development initiatives by biotechnology and pharmaceutical industry players are also driving the growth of the global cancer registry software market.

Cancer Registry Software Market Recent Developments

  • ArborMetrix Inc. U.S. announced a partnership with the Society of Interventional Radiology in June 2020. The goal of this collaboration is to provide the IR Quality Registry, which will integrate analytics to enhance patient care.
  • COVID-19 registration platform and technology powered trial matching solution was launched by IQVIA Holdings Inc. in April 2020.
  • Elekta partnered with PalabraApps LLC in April 2018 to develop the software that powers its MOSAIQ Oncology Information System.
  • Onco Inc. increased its revenue in November 2018 by upgrading Oncology Version 4.4.0 to meet new CoC, AJCC 8th, SEER, NAACCR 18, and STORE standards.

Cancer Registry Software Market Companies

  • Rocky Mountain Cancer Data Systems
  • McKesson Corporation
  • Onco Inc.
  • Elekta AB
  • IBM Corporation
  • C/Net Solutions
  • Ordinal Data Inc.
  • Himagine Solutions Inc.
  • Electronic Registry Systems Inc.
  • CONDUENT Inc.

Segments Covered in the Report

By Software

  • Cross disciplinary
  • Specific

By Deployment Model

  • On-premise
  • Cloud-based

By Component

  • Commercial
  • Public

By End Use

  • Government and third party
  • Private payers
  • Hospital and medical practice
  • Pharma biotech and medical device companies
  • Research institutes

By Functionality

  • Cancer Reporting to Meet State & Federal Regulations
  • Patient Care Management
  • Product Outcome Evaluation
  • Medical Research and Clinical Studies

By Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Malaysia
    • Philippines
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC
    • North Africa
    • South Africa
    • Rest of the Middle East & Africa

Frequently Asked Questions

The global cancer registry software market size was reached at USD 59.02 million in 2023 and is anticipated to rake USD 143.62 million by 2033.

The global cancer registry software market is expanding growth at a CAGR of 9.3% from 2024 to 2033.

The major players operating in the cancer registry software market are Rocky Mountain Cancer Data Systems, McKesson Corporation, Onco Inc., Elekta AB, IBM Corporation, C/Net Solutions, Ordinal Data Inc., Himagine Solutions Inc., Electronic Registry Systems Inc., and CONDUENT Inc.

One of the key factors driving the growth of the global cancer registry software market is growing incidence of cancer globally. The growing geriatric population is also driving the growth of the cancer registry software market over the forecast period.

North America region will dominate the cancer registry software market during the forecast period 2024 to 2033.

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Cancer Registry Software Market 

5.1. COVID-19 Landscape: Cancer Registry Software Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Cancer Registry Software Market, By Software Type

8.1. Cancer Registry Software Market, by Software Type, 2024-2033

8.1.1. Cross disciplinary

8.1.1.1. Market Revenue and Forecast (2021-2033)

8.1.2. Specific

8.1.2.1. Market Revenue and Forecast (2021-2033)

Chapter 9. Global Cancer Registry Software Market, By Deployment Model Type

9.1. Cancer Registry Software Market, by Deployment Model Type, 2024-2033

9.1.1. On-premise

9.1.1.1. Market Revenue and Forecast (2021-2033)

9.1.2. Cloud-based

9.1.2.1. Market Revenue and Forecast (2021-2033)

Chapter 10. Global Cancer Registry Software Market, By End Use Type 

10.1. Cancer Registry Software Market, by End Use Type, 2024-2033

10.1.1. Government and third party

10.1.1.1. Market Revenue and Forecast (2021-2033)

10.1.2. Private payers

10.1.2.1. Market Revenue and Forecast (2021-2033)

10.1.3. Hospital and medical practice

10.1.3.1. Market Revenue and Forecast (2021-2033)

10.1.4. Pharma biotech and medical device companies

10.1.4.1. Market Revenue and Forecast (2021-2033)

10.1.5. Research institutes

10.1.5.1. Market Revenue and Forecast (2021-2033)

Chapter 11. Global Cancer Registry Software Market, By Functionality Type

11.1. Cancer Registry Software Market, by Functionality Type, 2024-2033

11.1.1. Cancer Reporting to Meet State & Federal Regulations

11.1.1.1. Market Revenue and Forecast (2021-2033)

11.1.2. Patient Care Management

11.1.2.1. Market Revenue and Forecast (2021-2033)

11.1.3. Product Outcome Evaluation

11.1.3.1. Market Revenue and Forecast (2021-2033)

11.1.4. Medical Research and Clinical Studies

11.1.4.1. Market Revenue and Forecast (2021-2033)

Chapter 12. Global Cancer Registry Software Market, By Component Type

12.1. Cancer Registry Software Market, by Component, 2024-2033

12.1.1. Commercial

12.1.1.1. Market Revenue and Forecast (2021-2033)

12.1.2. Public

12.1.2.1. Market Revenue and Forecast (2021-2033)

Chapter 13. Global Cancer Registry Software  Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Forecast, by Software (2021-2033)

13.1.2. Market Revenue and Forecast, by Deployment Model (2021-2033)

13.1.3. Market Revenue and Forecast, by End Use (2021-2033)

13.1.4. Market Revenue and Forecast, by Functionality (2021-2033)

13.1.5. Market Revenue and Forecast, by Component (2021-2033)

13.1.6. U.S.

13.1.6.1. Market Revenue and Forecast, by Software (2021-2033)

13.1.6.2. Market Revenue and Forecast, by Deployment Model (2021-2033)

13.1.6.3. Market Revenue and Forecast, by End Use (2021-2033)

13.1.6.4. Market Revenue and Forecast, by Functionality (2021-2033)

13.1.7. Market Revenue and Forecast, by Component (2021-2033) 

13.1.8. Rest of North America

13.1.8.1. Market Revenue and Forecast, by Software (2021-2033)

13.1.8.2. Market Revenue and Forecast, by Deployment Model (2021-2033)

13.1.8.3. Market Revenue and Forecast, by End Use (2021-2033)

13.1.8.4. Market Revenue and Forecast, by Functionality (2021-2033)

13.1.8.5. Market Revenue and Forecast, by Component (2021-2033)

13.2. Europe

13.2.1. Market Revenue and Forecast, by Software (2021-2033)

13.2.2. Market Revenue and Forecast, by Deployment Model (2021-2033)

13.2.3. Market Revenue and Forecast, by End Use (2021-2033)

13.2.4. Market Revenue and Forecast, by Functionality (2021-2033) 

13.2.5. Market Revenue and Forecast, by Component (2021-2033) 

13.2.6. UK

13.2.6.1. Market Revenue and Forecast, by Software (2021-2033)

13.2.6.2. Market Revenue and Forecast, by Deployment Model (2021-2033)

13.2.6.3. Market Revenue and Forecast, by End Use (2021-2033)

13.2.7. Market Revenue and Forecast, by Functionality (2021-2033) 

13.2.8. Market Revenue and Forecast, by Component (2021-2033) 

13.2.9. Germany

13.2.9.1. Market Revenue and Forecast, by Software (2021-2033)

13.2.9.2. Market Revenue and Forecast, by Deployment Model (2021-2033)

13.2.9.3. Market Revenue and Forecast, by End Use (2021-2033)

13.2.10. Market Revenue and Forecast, by Functionality (2021-2033)

13.2.11. Market Revenue and Forecast, by Component (2021-2033)

13.2.12. France

13.2.12.1. Market Revenue and Forecast, by Software (2021-2033)

13.2.12.2. Market Revenue and Forecast, by Deployment Model (2021-2033)

13.2.12.3. Market Revenue and Forecast, by End Use (2021-2033)

13.2.12.4. Market Revenue and Forecast, by Functionality (2021-2033)

13.2.13. Market Revenue and Forecast, by Component (2021-2033)

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Forecast, by Software (2021-2033)

13.2.14.2. Market Revenue and Forecast, by Deployment Model (2021-2033)

13.2.14.3. Market Revenue and Forecast, by End Use (2021-2033)

13.2.14.4. Market Revenue and Forecast, by Functionality (2021-2033)

13.2.15. Market Revenue and Forecast, by Component (2021-2033)

13.3. APAC

13.3.1. Market Revenue and Forecast, by Software (2021-2033)

13.3.2. Market Revenue and Forecast, by Deployment Model (2021-2033)

13.3.3. Market Revenue and Forecast, by End Use (2021-2033)

13.3.4. Market Revenue and Forecast, by Functionality (2021-2033)

13.3.5. Market Revenue and Forecast, by Component (2021-2033)

13.3.6. India

13.3.6.1. Market Revenue and Forecast, by Software (2021-2033)

13.3.6.2. Market Revenue and Forecast, by Deployment Model (2021-2033)

13.3.6.3. Market Revenue and Forecast, by End Use (2021-2033)

13.3.6.4. Market Revenue and Forecast, by Functionality (2021-2033)

13.3.7. Market Revenue and Forecast, by Component (2021-2033)

13.3.8. China

13.3.8.1. Market Revenue and Forecast, by Software (2021-2033)

13.3.8.2. Market Revenue and Forecast, by Deployment Model (2021-2033)

13.3.8.3. Market Revenue and Forecast, by End Use (2021-2033)

13.3.8.4. Market Revenue and Forecast, by Functionality (2021-2033)

13.3.9. Market Revenue and Forecast, by Component (2021-2033)

13.3.10. Japan

13.3.10.1. Market Revenue and Forecast, by Software (2021-2033)

13.3.10.2. Market Revenue and Forecast, by Deployment Model (2021-2033)

13.3.10.3. Market Revenue and Forecast, by End Use (2021-2033)

13.3.10.4. Market Revenue and Forecast, by Functionality (2021-2033)

13.3.10.5. Market Revenue and Forecast, by Component (2021-2033)

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Forecast, by Software (2021-2033)

13.3.11.2. Market Revenue and Forecast, by Deployment Model (2021-2033)

13.3.11.3. Market Revenue and Forecast, by End Use (2021-2033)

13.3.11.4. Market Revenue and Forecast, by Functionality (2021-2033)

13.3.11.5. Market Revenue and Forecast, by Component (2021-2033)

13.4. MEA

13.4.1. Market Revenue and Forecast, by Software (2021-2033)

13.4.2. Market Revenue and Forecast, by Deployment Model (2021-2033)

13.4.3. Market Revenue and Forecast, by End Use (2021-2033)

13.4.4. Market Revenue and Forecast, by Functionality (2021-2033)

13.4.5. Market Revenue and Forecast, by Component (2021-2033)

13.4.6. GCC

13.4.6.1. Market Revenue and Forecast, by Software (2021-2033)

13.4.6.2. Market Revenue and Forecast, by Deployment Model (2021-2033)

13.4.6.3. Market Revenue and Forecast, by End Use (2021-2033)

13.4.6.4. Market Revenue and Forecast, by Functionality (2021-2033)

13.4.7. Market Revenue and Forecast, by Component (2021-2033)

13.4.8. North Africa

13.4.8.1. Market Revenue and Forecast, by Software (2021-2033)

13.4.8.2. Market Revenue and Forecast, by Deployment Model (2021-2033)

13.4.8.3. Market Revenue and Forecast, by End Use (2021-2033)

13.4.8.4. Market Revenue and Forecast, by Functionality (2021-2033)

13.4.9. Market Revenue and Forecast, by Component (2021-2033)

13.4.10. South Africa

13.4.10.1. Market Revenue and Forecast, by Software (2021-2033)

13.4.10.2. Market Revenue and Forecast, by Deployment Model (2021-2033)

13.4.10.3. Market Revenue and Forecast, by End Use (2021-2033)

13.4.10.4. Market Revenue and Forecast, by Functionality (2021-2033)

13.4.10.5. Market Revenue and Forecast, by Component (2021-2033)

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Forecast, by Software (2021-2033)

13.4.11.2. Market Revenue and Forecast, by Deployment Model (2021-2033)

13.4.11.3. Market Revenue and Forecast, by End Use (2021-2033)

13.4.11.4. Market Revenue and Forecast, by Functionality (2021-2033)

13.4.11.5. Market Revenue and Forecast, by Component (2021-2033)

13.5. Latin America

13.5.1. Market Revenue and Forecast, by Software (2021-2033)

13.5.2. Market Revenue and Forecast, by Deployment Model (2021-2033)

13.5.3. Market Revenue and Forecast, by End Use (2021-2033)

13.5.4. Market Revenue and Forecast, by Functionality (2021-2033)

13.5.5. Market Revenue and Forecast, by Component (2021-2033)

13.5.6. Brazil

13.5.6.1. Market Revenue and Forecast, by Software (2021-2033)

13.5.6.2. Market Revenue and Forecast, by Deployment Model (2021-2033)

13.5.6.3. Market Revenue and Forecast, by End Use (2021-2033)

13.5.6.4. Market Revenue and Forecast, by Functionality (2021-2033)

13.5.7. Market Revenue and Forecast, by Component (2021-2033)

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Forecast, by Software (2021-2033)

13.5.8.2. Market Revenue and Forecast, by Deployment Model (2021-2033)

13.5.8.3. Market Revenue and Forecast, by End Use (2021-2033)

13.5.8.4. Market Revenue and Forecast, by Functionality (2021-2033)

13.5.8.5. Market Revenue and Forecast, by Component (2021-2033)

Chapter 14. Company Profiles

14.1. Rocky Mountain Cancer Data Systems

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. McKesson Corporation

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. Onco Inc.

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Elekta AB

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. IBM Corporation

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. C/Net Solutions

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. Ordinal Data Inc.

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Himagine Solutions Inc.

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Electronic Registry Systems Inc.

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. CONDUENT Inc.

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client